7/27/2020 8:19:47 AM
NGM Bio Begins Phase 2 CATALINA Study Of NGM621 In Patients With Geographic Atrophy Secondary To AMD
5/27/2020 4:17:36 PM
NGM Bio Appoints Siobhan Nolan Mangini As CFO
4/3/2019 9:08:43 PM
NGM Biopharma Prices IPO Of 6.67 Mln Shares At $16.00/shr